The successful development and deployment of companion diagnostics (CDx) requires effective interactions between four different parties: the therapeutic developer, the diagnostic manufacturer, the drug regulatory body, and the diagnostic regulatory body. Ensuring effective collaboration requires that the parties understand each other's roles, responsibilities, and goals. This article highlights therapeutic, diagnostic, and regulatory perspectives of CDx and emphasizes the importance of open and transparent communication to support successful collaboration and patient access to these critical therapeutic tools.
